From: Relationship between the area of isopters and Vigabatrin dosage during two years of observation
No | Age | Gender | Visual acuity | Mean daily dose of VGB (mg) | Cumulative dose of VGB (g) | Duration of VGB treatment (months) | Duration of follow-up (months) | Other antiepileptic drugs | Classification of the SKP visual field | |
---|---|---|---|---|---|---|---|---|---|---|
Right | Left | |||||||||
1 | 54 | M | 1.0 | 0.9 | 1800 | 1470 | 27 | 25 | OCZ | Normal |
2 | 23 | F | 1.0 | 1.0 | 1450 | 1050 | 24 | 24 | VPA, LTG | Normal |
3 | 41 | F | 1.0 | 1.0 | 1000 | 1230 | 21 | 24 | OCZ | Mildly abnormal |
4 | 53 | F | 1.0 | 1.0 | 1000 | 750 | 23 | 25 | VPA | Normal |
5 | 48 | F | 1.0 | 1.0 | 1500 | 1305 | 29 | 24 | CBZ, CLZ | Normal |
6 | 34 | M | 1.0 | 1.0 | 2100 | 1440 | 23 | 23 | VPA, CBZ | Normal |
7 | 27 | M | 1.0 | 1.0 | 1900 | 1710 | 29 | 25 | VPA, CBZ | Normal |
8 | 56 | F | 1.0 | 1.0 | 1000 | 1290 | 27 | 21 | CBZ | Normal |
9 | 59 | M | 0.7 | 1.0 | 2300 | 1365 | 24 | 24 | VPA | Mildly abnormal |
10 | 49 | F | 1.0 | 1.0 | 2000 | 1740 | 24 | 21 | CBZ | Normal |
11 | 48 | M | 1.0 | 1.0 | 1500 | 11305 | 24 | 22 | CBZ | Normal |
12 | 31 | F | 1.0 | 1.0 | 1000 | 300 | 11 | 14 | CBZ | Normal |
13 | 39 | F | 1.0 | 1.0 | 1000 | 6000 | 15 | 12 | CBZ | Normal |
14 | 35 | M | 1.0 | 1.0 | 1000 | 750 | 25 | 25 | CBZ | Normal |